After allo-SCT, analysis of CD34 þ lineage-specific donor cell chimerism (DCC) is a sensitive method for monitoring minimal residual disease in patients with AML or myelodysplastic syndrome (MDS) with CD34 expression. To substantiate evidence of whether immune interventions in patients with impending relapse, defined by incomplete lineage-specific DCC, may prevent hematological relapse, we performed a retrospective nested case control study. Unsorted and lineage-specific DCC were measured in 134 patients. Forty-three patients had an incomplete CD34
INTRODUCTION
With the introduction of reduced-intensity conditioning (RIC), high-resolution HLA-typing, matched-unrelated donor transplantation, and improvement of supportive care within the last few decades, a new era of allo-SCT has been opened. These significant developments are responsible for marked reduction of treatmentrelated toxicities and allowed broadening of the indication for allo-SCT to patients at a higher age and/or with significant comorbidity. 1, 2 Along with this progress, reported non relapserelated mortality (NRM) as high as 20-30% may jeopardize the potential of allo-SCT. 3 At least for patients with acute AML transplanted in first CR, some RIC regimens allow the reduction of NRM to 10% or less, without increasing the risk of relapse. 4 However, with relapse incidences exceeding up to 50%, for example, for patients with high-risk AML, relapse has become the leading cause of treatment failure after allo-SCT. 5 Once overt relapse has occurred, different treatment strategies are being evaluated, including the reduction of immunosuppressive therapy, DLI, chemotherapy with or without subsequent DLI or second allo-SCT. In addition, drugs such as 5-azacitidine or tyrosine-kinase inhibitors with or without additional cellular immune intervention have also shown some benefit. 6, 7 Nevertheless, in cases of hematological relapse therapeutic interventions provide only a small chance for cure accompanied by high rates of morbidity and mortality. Importantly, success of the treatment depends heavily on the tumor burden and the kinetics of the underlying disease. 8 Given the unsatisfying overall results after treatment for recurrent AML or myelodysplastic syndrome (MDS), prevention of relapse after allo-SCT is the approach most likely to improve survival. Various attempts for monitoring minimal residual disease (MRD) to identify patients at risk for relapse have therefore been explored. However, only 30-50% of cases with AML and high-risk MDS undergoing allo-SCT have known leukemia-specific mutations that can be monitored by sensitive PCR techniques. [9] [10] [11] [12] Donor chimerism analyses of whole-blood or BM cells, as an alternative method for measuring MRD after allo-SCT, is usually compromised by low sensitivity. In contrast, lineage-specific donor chimerism analysis of flow cytometry-sorted CD34 þ cells are highly specific for monitoring MRD in diseases with CD34 expression on malignant cells. [13] [14] [15] [16] 
PATIENTS AND METHODS Patients
Between May 1999 and February 2011, 290 patients with AML (n ¼ 264) or MDS (n ¼ 26) were transplanted in our institution. Written informed consent was obtained from each patient before transplantation. For this retrospective nested case control study, patients with a follow-up of more than 100 days after allo-SCT and three or more informative chimerism analyses of BM cell subsets were included. In total, 134 patients matched those criteria (126 with AML and 8 with MDS, Table 1 ).
Conditioning regimen, graft and immunosuppressive therapy
Fifty-one percent (n ¼ 69) of all included patients received dose adapted or RIC regimens, mainly consisting of fractionated TBI (fTBI) with 8 Gy and fludarabine, or either treosulfan or BU i.v in combination with fludarabine. Standard-intensity conditioning, mainly consisting of fractionated 12 Gy TBI and CY was employed in 16% (n ¼ 22). Thirty-two percent of the patients (n ¼ 43), mainly with active disease at transplant, received sequential conditioning regimens with combinations of fludarabine, cytarabine, amsacrine, CY and 4 Gy fTBI (FLAMSA-RIC) or high-dose melphalan, followed by fludarabine and fTBI (8 Gy) . One hundred and twenty-seven patients were transplanted with G-CSF mobilized stem cells and seven patients received BM grafts. Antithymocyte globulin (ATG Fresenius Biotech, Munich, Germany ) was administered as prophylaxis for acute and chronic GVHD in 103 patients. As further GVHD prophylaxis, all patients received CSA in combination with a short course of MTX or with mycophenolate mofetile.
Post-transplant monitoring
Chimerism analysis was performed at our transplant laboratory. As described previously, a semiquantitative PCR approach based on the amplification of STR markers was used for analysis. 13 Briefly, pre-enrichment of CD34 þ cells using magnetic beads and subsequent FACS was performed. Simultaneously, overall BM chimerism was measured together with additional subset analyses of CD3 þ , CD19 þ and CD14 þ cells. Routine analysis of BM also consisted of morphological examination of BM smears, immunophenotyping and in the case of known markers, molecular-or cytogenetic analysis. Analyses were recommended every 3 months in the first year and every 3-6 months in the second year after allo-SCT. According to the individual risk factors and the clinical course, the first BM chimerism analysis was performed between day 30 and 100 after allo-SCT (Supplementary Figure) . Chimerism in peripheral blood (whole-blood samples) was assayed monthly for the first year, and every 2-3 months thereafter.
Genomic DNA for multiplex PCR of microsatellite markers was extracted directly from total mononuclear cells or from purified. Nine tetranucleotide microsatellite regions were coamplified with dye-labeled primers using the AmpFLSTR Profiler PCR amplification kit (Applied Biosystems, Weiterstadt, Germany). 17 Stable donor cell chimerism (DCC) was defined as X90% donor cell in every analyzed BM subset. In case of a DCC o90% in the CD34 þ subset and/or in unsorted BM samples (incomplete DCC), BM blast o5% and no evidence of extramedullary AML manifestation, an impending relapse was assumed. 13 
Immune interventions/immunotherapy
For patients without exceeding grade I acute or limited chronic GVHD, diagnosed with impending relapse and still receiving immunosuppressive treatment, immune intervention consisted of rapid tapering of systemic immunosuppressive medication. Subsequently, if lineage specific chimerism did not increase 490%, DLI was considered, if available. For patients without immunosuppressive treatment at time of detection of incomplete DCC, DLI were suggested as frontline treatment.
Statistical analyses
Data were analyzed as of July 1, 2011. OS was calculated from the day of transplantation to death by any cause, with patients alive at the time of last follow-up being censored. Relapse-free survival (RFS) was counted from the day of transplantation to relapse or death. Both, OS and RFS were estimated by Kaplan and Meier curves. Probabilities of decreasing/instable lineage-specific DCC, NRM (defined as non-relapse death/patients analyzed) and relapse were calculated using cumulative incidence estimates to accommodate competing risks. For statistical comparisons of group characteristics (for example, AML risk category, donor type, conditioning), w 2 analysis was used. Differences in estimated OS and RFS between subgroups were evaluated using the log-rank test and for multivariate analyses by logistic and Cox regression.
RESULTS

Patients and outcome according to chimerism status
Median follow-up of the 134 patients included in this analysis was 1030 days (surviving patients, range: 148-3674). The cumulative relapse incidence after 3 years for all patients was 30% (40/134 patients). The median time to overt relapse from time of transplant was 248 days (range 97-1133).
At initial diagnosis, leukemic blasts from 111/134 patients (83%) showed expression of CD34 þ in FACS analysis. In control patients (n ¼ 91/134), defined by stable DCC before hematological relapse or throughout the observational period, cumulative relapse incidence and NRM at 3 years (median follow-up of surviving patients 1032 days, range: 167-3166) was 20% and 6%, respectively ( Figure 3 ).
Impending relapse with an incomplete CD34 þ -subset DCC was detected in 43 patients. All patients showed a stable linage specific DCC for the CD3 Linage specific donor cell chimerism F Rosenow et al subpopulations. These patients had a cumulative relapse incidence at 3 years (median follow-up 972 days) of 51% ( Table 2) . The median time from transplantation to diagnosis of incomplete CD34
þ -lineage specific DCC was 111 days (range: 38-733), with a median time to consecutive relapse of 56 days (range: 14-546, Figure 1 ). All patients with incomplete CD34 þ -lineage specific DCC had at least one complete DCC measured from peripheral blood before diagnosis of impending relapse. Six patients showed an incomplete CD34 þ -lineage specific DCC in the first BM chimerism analysis (between day 38 and 62 after SCT), while all other patients showed at least one complete DCC from BM chimerism analysis before detection of impending relapse.
Four out of those 43 patients did not receive immune intervention, mainly due to relapse before DLI were available and as they already were without immunosuppression. In the other 39 patients receiving immune intervention (Supplementary Figure) , conversion to complete DCC could be achieved in 25 patients (56% response rate of the 43 patients with impending relapse). Immune intervention consisted of rapid tapering of immunosuppressive treatment in 29 patients and/or DLI infusions in 10 patients (one patient received donor lymphocytes after rapid tapering of immunosuppressive treatment).
Five out of 29 patients (17%) developed acute GVHD (three patients) or showed GVHD progression (two patients) after rapid tapering of immunosuppression. None of these patients relapsed. After infusion of donor lymphocytes, no clinically relevant acute or chronic GVHD occurred in our patients. Of the 10 patients receiving DLI, seven patients relapsed with their AML.
Despite immune intervention 14/39 patients (36%) relapsed without achieving complete DCC (median time from diagnosis of impending relapse to hematological relapse 55 days) and four patients relapsed after achieving complete DCC. All four patients without immune intervention relapsed within 20-69 days after incomplete DCC was detected.
Patients with a stable DCC showed a significant higher estimated RFS rate after 3 years of 74% (95% CI 64-83%) as compared with 40% (95% CI 24-58%) patients with incomplete CD34 þ -DCC (Po.05). The estimated OS rates differed significantly also between the two groups with 79% (95% CI 70-88%) and 52% (95% CI 35-69%), respectively (P o0.05, Figure 2 ). Molecular-and cytogenetic monitoring of MRD Disease specific molecular genetic markers where identified in 11 of 43 patients (two patients with NPM-mutation, three patients with FLT3-ITD-mutation, three patients with NPM-and additional FLT3-ITD-mutation, two patients with MLL-mutation and one patient with CBF-beta-MYH11-mutation). Four of these patients had additional AML-associated cytogenetic aberrations (complex karyotype, inv16, trisomy 11 and 8).
At time of isolated decrease in CD34 þ -DCC, 9 of these 11 patients were tested negative for their known molecular genetic marker (no analysis performed for two patients). Four of the 11 patients relapsed 40-79 days later. Of these patients one was not tested for his molecular marker at time of hematological relapse, one patient remained negative for his former known marker, and two patients showed reappearance of their molecular genetic markers (one patient with a FLT3-ITD mutation, one patients with a FLT3-ITD and a NPM1-mutation).
Of the 43 patients with impending relapse, 19 patients had known cytogenetic abnormalities at first diagnosis of AML/MDS. At the time of first isolated decrease in CD34 þ -DCC, 7/19 patients showed recurrence of their AML-associated karyotype. þ -lineage specific DCC (n ¼ 39, solid line), with patients who did not receive preemptive intervention (n ¼ 4, dotted line).
Linage specific donor cell chimerism F Rosenow et al
Hematological relapse occurred in four of those seven patients (57%) 14-49 days after suspected impeding relapse. One patient converted to complete DCC but relapsed 546 days after first decrease of CD34 þ -DCC. Two patients converted to complete DCC after immune intervention with no detection of their cytogenetic markers and no signs of hematological relapse.
Of the 12 patients without recurrence of their cytogenetic marker at time of first isolated decrease in CD34 þ -DCC, five patients (42%) relapsed 54-168 days later. At relapse, known cytogenetic abnormalities could be identified in three of the five patients and one patient showed a clonal evolution with a complex karyotype.
GVHD and NRM Grade I-IV acute GVHD occurred in 66 of 134 patients (49%) after transplantation and 42 patients (31%) developed chronic GVHD.
The cumulative incidences of acute GVHD did not differ between patients in the control group and the patients showing incomplete CD34 þ -lineage specific DCC. A trend of higher incidences of limited disease (19%) or extensive (17%) chronic GVHD was found in the control group, compared with 12 and 10% in the group with incomplete CD34 þ -lineage-specific DCC (Table 2 ). Cumulative incidence of NRM after 1 and 3 years after transplantation was 1 and 6% in the control group and 0 and 3% for patients with incomplete CD34 þ -lineage specific DCC, respectively ( Figure 3 ).
Outcome of AML-patients according to chimerism, remission status, donor, conditioning regimens and cytogenetic risk Of 126 patients with AML, 40 patients had evidence of an impending relapse according to CD34 þ lineage specific DCC and 18 patients relapsed with having a stable DCC before relapse. In nine of the 18 patients, AML blasts did not express CD34 at the time of relapse. The estimated RFS and OS rates at 3 years for control patients (stable DCC until last follow-up or stable DCC until hematological relapse, 86 patients) were 75% (95% CI 65-84%) and 80% (95% CI 71-90%) and for patients with impending relapse (40 patients) 35% (95% CI 18-53%) and 48% (95% CI 30-65%), respectively (Po0.001)
In further univariate analyses, donor (matched sibling vs unrelated donor), age at transplant (o40 years vs X40 years), remission status at transplant (remission vs active disease), and conditioning regimens (RIC vs standard-intensity conditioning vs sequential conditioning) were not associated with differences in RFS rates (Table 3) . Only an adverse cytogenetic risk profile at diagnosis showed a trend towards an inferior outcome (Po0.071).
A multivariate Cox proportional hazards analysis for OS and RFS including the covariate status of chimerism as a time-depended variable, remission status before transplantation, type of donor, age and cytogenetic-risk category revealed only chimerism status as an independent poor prognostic factor (for OS: P o0.001, risk ratio, 3.81, 95% CI 1.95-7.44; for RFS: Po0.001, risk ratio, 5.57, 95% CI 3.98-10.41). With regard to NRM none of these factors were of prognostic relevance, whereas with regard to risk of relapse, chimerism status was an independent poor prognostic factor (P o0.001, risk ratio, 5.57, 95% CI 2.98-10.41).
DISCUSSION
Our retrospective, nested case control study demonstrated that monitoring of CD34 þ -lineage specific DCC, was a prognostic and predictive diagnostic tool for the identification of patients with AML or MDS, at risk for hematological relapse after allo-SCT. Furthermore, our data highly suggested that immune intervention based diagnosis of incomplete CD34 þ -lineage specific DCC, led to the conversion into complete DCC and therefore prevented overt hematological relapse.
Compared with chimerism analyses from whole BM or blood samples, lineage specific chimerism analysis of the Linage specific donor cell chimerism F Rosenow et al CD34 þ -subpopulation of AML patients after allo-SCT, has been demonstrated to be highly sensitive and specific for the detection of impending relapse. [13] [14] [15] AML patients commonly express CD34 Ag (70-75%) on their malignant cells and in some cases the leukemic immunophenotype can alter from diagnosis to relapse. 18, 19 Our analysis included patients with CD34 Ag expressing AMLs and 23 patients with, at first diagnosis CD34
À AML (all of these patients were in the control group with stable DCC), which might be a limitation of lineage-specific DCC analysis in this subgroup. However, as gain of CD34 expression is more common than its loss, we also applied CD34 þ -lineage-specific DCC analysis in patients with leukemic blasts not expressing CD34 at initial diagnosis. 18 Different approaches of monitoring of MRD after allo-SCT for AML patients have been described. 11, 20 Cytogenetic analyses are standard methods in the initial diagnostic evaluation and allow the detection of chromosome abnormalities in B55% of adult AML patients. 12 Although this technique provides a very highly specific tool, the sensitivity to detect impending relapse seems to be rather low. 21 In our cohort, only a few patients showed recurrence of their known cytogenetic marker at time of suspected impending relapse. Moreover, only half of the patients with subsequent overt relapse showed reappearance of the disease-related cytogenetic markers at time of incomplete CD34 þ -lineage specific DCC. With the growing number of identified leukemia-specific targets (for example, gene fusions, gene mutations, overexpressed genes), monitoring of MRD before and after allo-SCT by real-time PCR detecting is an active field of investigation. 22 In more than 85% of patients with AML and normal cytogenetics findings, molecular genetic alterations can be detected. The most frequent mutation of the NPM1 gene is found in about 30% of patients with AML. that MRD positive patients after consolidation therapy have a significantly higher cumulative incidence of relapse, compared with MRD negative patients (15% vs 66%).
Another frequently found molecular abnormality is the internal tandem duplication of the FLT3 gene (FLT3-ITD), positive in about 35-45% of patients with normal karyotype. However, after allo-SCT the use of FLT3-ITD as a molecular marker is controversial for two major reasons: the individual mutation requires a patientspecific primer to use quantitative PCR monitoring and the genomic instability leads to a loss of the mutation in about 20% of patients after relapse.
11
Besides NPM1 and FLT3 mutations, a broad panel of molecular markers is detectable in AML, for example, intragenic mutations of the MLL gene, mutation in the RUNX1 gene, mutations in IDH1 and IDH2 gene and different mutations in the CEBPA gene. 12 Studies on the role of these markers after allo-SCT are still lacking.
With the combination of DCC analyses of unsorted or CD34
þ -sorted cells with the Wilms' tumor gene 1 expression, Lange et al. 25 tested these markers as significant predictors of relapse with sensitivities ranging from 53-79% and specificities of 82-91%. However, a comparison of Wilms' tumor gene 1 expression and NPM1 mutation levels in AML patients by Barragan et al. 26 revealed that in contrast to Wilms' tumor gene 1, which maintained its' residual expression levels, NPM1 was undetectable in patients with stable remission.
Compared with studies that mainly evaluated the prognostic value of different MRD markers, including DCC after allo-SCT in adult patients with AML, our study also verified the predictive value of MRD measurements with regard to therapeutic interventions. As a consequence of the rather low response rates to immunotherapy after hematological relapse following allo-SCT, early detection of impending relapse seems even more important. 8, 27 Low-tumor burden, defined by the blast count in BM aspirates, is one of the important prognostic factors for successful immune intervention like donor cell infusion. With our time schedule of MRD evaluation, we were able to detect impending relapse at a median of 55 days before consecutive hematological relapse. This gave us the chance to apply different immunotherapeutic approaches in 91% of the patients with decreasing or incomplete lineage-specific DCC. With a 64% success rate, defined by reconversion in complete DCC, our results are comparable to recently published results from a prospective study in children with AML. 28 In a retrospective analysis, Sairafi et al. 29 were also able to demonstrate that early immune intervention in case of impending relapse was more effective compared with late intervention after overt relapse. Nevertheless, even with immune intervention the survival of the group with incomplete CD34 þ lineage-specific DCC was inferior to the survival of the control group with stable DCC.
One major advantage of our approach was the general use of lineage-specific DCC analysis for follow-up monitoring of AML patients after allo-SCT. By using FACS-sorted subpopulations of BM aspirates for PCR-based chimerism analysis, this method provides a highly sensitive approach for detection of decreasing DCC and in patients with CD34-positive AML an informative tool for early detection of MRD. Our results are in line with the data published by Bornhauser et al., 15 which highly suggested that monitoring of CD34-positive DCC in the peripheral blood allows prediction of imminent relapse after allo-SCT, even when disease-specific markers are lacking. However, the diagnostic value of measuring chimerism in peripheral blood compared with BM has to be confirmed in a larger study cohort. Noteworthy, all patients in our study population had a stable DCC in the unsorted peripheral blood and BM at the time of first diagnosis of impending relapse or before hematological relapse. Moreover, even the FACS-sorted subpopulations of CD3, CD14 or CD19 positive BM cells were not informative with regard to impending relapse.
By including only patients in our analysis, who survived more than 100 days after allo-SCT and who had at least three informative chimerism results, we certainly have a highly selected cohort of patients. Consequently, survival status was mainly influenced by relapse and not by death related to early toxicities. Most likely due to this selection, status of CD34 þ -lineage specific DCC remained the only independent risk factor in a multivariate model. AML risk categories according to the initial cytogenetic finding, showed a trend towards a better outcome of patients with an intermediate risk profile compared with those with a poor-risk profile. Interestingly, by selection of patients with a longer followup, who consequently had only low incidences of toxicity-/nonrelapse related death, remission status prior transplantation did not influence RFS.
In summary, CD34 þ -lineage-specific DCC analysis for follow-up monitoring (every 2-3 months in the first years and every 3-6 months in the second year) for at least 2 years after allo-SCT for patients with AML or MDS is an important tool for detecting MRD and can provide guidance for immunotherapy for prevention and early treatment of hematological relapse at the time of low-tumor burden. A limitation of our study was the lack of a sufficient control group, as all patients were monitored for lineage-specific DCC. With the growing availability of different methods for MRD detection and the limited options of sufficient treatments for overt relapse, a control group without MRD measurement and/or without therapeutic intervention in case of impending relapse, would be unethical.
